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AbstrACt
Introduction Acute severe ulcerative colitis (ASUC) is a 
severe manifestation of ulcerative colitis (UC) that warrants 
hospitalisation. Despite significant advances in therapeutic 
options for UC and in the medical management of steroid-
refractory ASUC, the initial treatment paradigm has not 
changed since 1955 and is based on the use of intravenous 
corticosteroids. This treatment is successful in approximately 
50% of patients but failure of this and subsequent medical 
therapy still occurs, with colectomy rates of up to 40% 
reported. The Interleukin 1 (IL-1) blockade in Acute Severe 
Colitis (IASO) trial aims to investigate whether antagonism 
of IL-1 signalling using anakinra in addition to intravenous 
corticosteroid treatment can improve outcomes in patients 
with ASUC.
Methods and analysis IASO is a phase II, multicentre, two-
arm (parallel group), randomised (1:1), placebo-controlled, 
double-blinded trial of short-duration anakinra in ASUC. 
Its primary outcome will be the incidence of medical (eg, 
infliximab/ciclosporin) or surgical rescue therapy (colectomy) 
within 10 days following the commencement of intravenous 
corticosteroid therapy. Secondary outcomes will include 
disease activity, time to clinical response, time to rescue 
therapy, colectomy incidence by day 98 post intravenous 
corticosteroids and safety. The trial aims to recruit 214 
patients across 20 sites in the UK.
Ethics and dissemination The trial has received approval 
from the Cambridge Central Research Ethics Committee (Ref: 
17/EE/0347), the Health Research Authority (Ref: 201505) and 
Clinical Trials Authorisation from the Medicines and Healthcare 
products Regulatory Agency. We plan to present trial findings 
at scientific conferences and publish in high-impact peer-
reviewed journals.
trial registration number ISRCTN43717130; EudraCT 2017-
001389-10.
IntroduCtIon  
background and rationale
Ulcerative colitis (UC) is an inflamma-
tory condition of the colon associated with 
diarrhoea, rectal bleeding and abdominal 
pain. UC affects around 120 000 people in 
the UK.1 UC tends to follow a relapsing/
remitting course with periods of compara-
tive health interspersed with unpredictable 
acute ‘flares’. These may be severe enough to 
mandate hospital admission. For patients with 
UC in the UK, annual hospitalisation rates 
with acute severe UC (ASUC) are around 3% 
(3600 individuals). Twenty to forty per cent of 
these patients will require emergency surgical 
removal of the colon (colectomy) during 
the same hospital admission.2 3 A recent UK 
audit of emergency surgery in colitis showed 
mortality rates of 4% at 90 days.4 Additionally, 
surgery carries significant morbidity associ-
ated with the need for at least a temporary 
stoma, as well as long-term complications 
(both physical (eg, adhesional disease) and 
psychological) and complications of subse-
quent procedures (eg, pelvic nerve damage 
with ileal pouch-anal anastomosis or comple-
tion proctectomy).
Treatment for ASUC involves high-dose 
intravenous corticosteroids and is stan-
dardised worldwide.5 After 3–5 days, patients 
who do not exhibit an improvement may 
strengths and limitations of this study
 ► A multicentre, UK-wide trial of 214 participants at 
20 sites.
 ► The largest first-line treatment study ever conduct-
ed in this patient group.
 ► Potential for a step change and improved outcomes 
in patients with acute illness, including cost savings 
for the National Health Service.
 ► Pragmatic trial with wide eligibility criteria.
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be considered for medical ‘rescue’ therapy with further 
immunosuppression using either infliximab or ciclo-
sporin. Those patients who subsequently fail to respond 
to medical treatment, or patients with fulminant colitis at 
presentation, will then proceed to surgery, typically within 
the space of 4–10 days of rescue therapy initiation. This is 
usually performed on the same admission with a subtotal 
colectomy and creation of an end ileostomy.
The initial management of ASUC has changed little 
since the seminal trial of intravenous corticosteroids in 
1955.6 Despite significant advances in therapeutic options 
and drug development for ambulatory patients with UC, 
patients with ASUC are typically excluded from the eligi-
bility criteria of standard clinical trials for patients with 
moderate to severe UC. Clinical trials that have compared 
infliximab or ciclosporin as medical rescue treatments for 
ASUC have required patients to fail to respond to treat-
ment with up to 5 days of intravenous steroids.7–9 In the 
absence of reliable early prognostic markers, it may be 
appealing to treat all patients presenting with ASUC with 
immunosuppressive treatments normally reserved for 
rescue therapy rather than corticosteroids alone. The 
barriers for this approach include the toxicity of such 
treatment10–13 as well as the financial burden incurred.14 
There is still therefore an unmet need to improve the 
management of ASUC by doing something at the point 
of initial treatment, rather than waiting for treatment 
failure.
One of the key mediators of colonic inflammation in 
ASUC is interleukin 1 (IL-1) which plays a pivotal role 
in local activation of neutrophils and a number of down-
stream inflammatory mediators.15 The IL-1 axis has been 
repeatedly identified as a therapeutic target in UC.16–18 
IL-1 antagonism occurs naturally via the ubiquitous 
IL-1 receptor antagonist (IL-1Ra). A recombinant form 
of this naturally occurring anti-inflammatory, anakinra 
(Kineret), has been used for the treatment of patients 
with rheumatoid arthritis (RA) and cryopyrin-associ-
ated periodic syndromes (CAPS) with good effect.19–22 
Anakinra has a very good safety profile in many disease 
states including RA, CAPS, severe sepsis and intracranial 
haemorrhage at standard subcutaneous dosing regimens 
and using high-dose intravenous administration regi-
mens.21 23 24
Our hypothesis is that antagonism of the IL-1 axis with 
anakinra is an effective way of abrogating the early inflam-
matory response seen in ASUC and leads to improved 
clinical outcomes.
There is evidence to suggest that anakinra cotreatment 
with corticosteroids may be beneficial, given that cortico-
steroids suppress the production of IL-1Ra to a greater 
extent than its active family members—IL-1α and IL-1β.25 
Moreover, while recent research has seen a trend towards 
antagonism of IL-1 using monoclonal antibodies,17 anak-
inra may offer some advantages. First, its relative short 
half-life (4–6 hours) compared with antibodies allows 
early institution of further immunosuppression therapy if 
rescue therapy is required. Second, anakinra antagonises 
both IL-1α and IL-1β, while monoclonal antibodies are 
specific to either form. Finally, given that the patent for 
anakinra is now expired, the cost of the product is much 
less than that of the monoclonal antibody alternatives.26 27 
Given this evidence, antagonism of IL-1 early in the course 
of inflammation, in conjunction with standard cortico-
steroid treatment, is a promising therapeutic avenue in 
patients with ASUC.
Aims and objectives
The Interleukin 1 blockade in Acute Severe Colitis 
(IASO) trial aims to test whether anakinra can reduce the 
need for medical or surgical rescue therapy in patients 
with ASUC when given alongside intravenous corticoste-
roids. The trial also aims to assess the effects of anakinra 
on disease biology and bowel inflammation in addition to 
assessing drug safety, longer term health and patient-re-
ported quality of life outcomes. Finally, the trial will seek 
to advance scientific understanding of ASUC through 
the collection and analysis of a large range of biological 
samples, including blood and tissue transcriptomic anal-
ysis, as well as microbial analysis. As part of this work, 
we will attempt to validate a transcriptional predictor of 
outcomes in UC that we have previously reported.28
Primary objective
To compare the clinical effects of anakinra with placebo 
when given in addition to current standard care in 
patients with ASUC.
Secondary objective
To compare the effects of anakinra with placebo when 
given in addition to current standard care to patients with 
ASUC in terms of:
 ► Safety.
 ► Need for colectomy.
 ► Patient-reported outcomes.
 ► Endoscopic and histological evidence of treatment 
effects.
 ► Evidence of disruption of the IL-1 signalling pathway.
This article summarises the approved trial protocol in 
use at the time of submission (version 2.0, dated 25 May 
2018). The full version of the protocol can be found in 
the online supplementary material 1. The most current 
version of the protocol will be made available online at 
https://www. journalslibrary. nihr. ac. uk/ programmes/ 
eme/ 1420102/#/.
MEthods
trial design and flow chart
IASO is a multicentre, two-arm (parallel group), 
randomised, placebo-controlled, double-blinded trial. 
The trial will also feature a substudy specifically exam-
ining the endoscopic effects of treatment with anakinra in 
comparison with placebo. A summary of the trial design is 
shown in figure 1.
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Figure 1 Interleukin 1 blockade in Acute Severe Colitis (IASO) trial flow chart. *Data collection for the primary endpoint and 
the colectomy-specific secondary endpoint is performed at days measured relative to the start of IMP treatment. However, 
the subsequent data analysis will assess these endpoints using time relative to the earlier start of intravenous corticosteroid 
treatment. CMV, cytomegalovirus; CUCQ-32, Crohn’s and Ulcerative Colitis Questionnaire-32; EQ-5D, EuroQol five dimensions; 
GI, gastrointestinal; IMP, investigational medicinal product; IV, intravenous; MTWSI, modified Truelove and Witts severity index; 
SAE, serious adverse event; SC, subcutaneous. 
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Centres
IASO is a multicentre study in UK National Health Service 
(NHS) acute hospitals. We plan to include approximately 
20 centres in the trial.
All sites will recruit, treat and follow-up participants 
equally, but a subset of sites will also recruit participants 
into the optional endoscopic substudy involving one addi-
tional flexible sigmoidoscopy with biopsy collection.
trial duration
Participants’ involvement in the trial will last approx-
imately 6 months. This includes an initial treatment 
period of approximately 5–7 days, during which 
screening and an investigational medicinal product 
(IMP) treatment course of up to 5 days will be 
completed. Review of participant outcomes following 
trial participation may continue for up to 5 years using 
Hospital Episode Statistics (HES) data, without any 
additional burden to the participant. Any HES data 
collection would start at 1 year after commencement 
of IMP treatment and examination of outcomes via 
HES data would potentially continue for up to 5 years, 
depending on study outcomes. A yearly assessment of 
HES outcomes by the Trial Steering Committee (TSC) 
would determine whether collection of HES data 
should continue.
Participant selection
Inclusion criteria
To be included in the trial the participant must:
 ► Be aged 16–80 years inclusive.
 ► Have given written informed consent to participate.
 ► Be hospitalised with clinically confirmed or suspected 
ASUC and a modified Truelove and Witts severity 
index (MTWSI)7 score ≥11.
 ► Have a requirement for treatment with intravenous 
corticosteroids in the judgement of the treating clini-
cian, with the possibility to receive a first dose of IMP 
within 36 hours of commencement of intravenous 
corticosteroids.
There are no validated clinical scoring systems for 
ASUC. We selected the MTWSI (also known as the Lich-
tiger index) with a cut-off of ≥11 since this aligns with 
the score used in index studies of ciclosporin in ASUC,7 
as well as in the CycloSporine versus InFliximab (CySIF), 
and Comparison of Infliximab and Ciclosporin in 
Steroid Resistant Ulcerative Colitis (CONSTRUCT) trials 
comparing ciclosporin and infliximab.9 29 The compo-
nents of the MTWSI include those parameters that are 
relevant to clinical decision-making for initial recognition 
of ASUC and for determination of the need for rescue 
therapy (see online supplementary material 2).
Exclusion criteria
The presence of any of the following will preclude partic-
ipant inclusion:
 ► Pregnant or breastfeeding women.
 ► Oral corticosteroid dosing for a duration of 8 weeks or 
more immediately prior to commencement of intrave-
nous corticosteroid dosing.
 ► History of severe hepatic impairment (eg, Child-
Pugh grade C).
 ► Moderate or severe renal impairment (esti-
mated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2).
 ► Neutropenia (neutrophil count <1.5×109/L).
 ► Previous treatment with anakinra for any indication.
 ► Documented hypersensitivity to the active substance 
or to any of the excipients or to Escherichia coli-derived 
proteins; latex allergy.
 ► Evidence (eg, blood cultures) or clinical suspicion 
of systemic infection (Concurrent prescription of 
antibiotics to cover for the possibility of gastroin-
testinal (GI) infection while awaiting stool culture 
results, or the possibility of bacterial translocation 
relating to severe colitis, is not an exclusion criterion 
where the physician suspects UC is the most likely 
diagnosis).
 ► Current or previous cytomegalovirus (CMV) infection 
requiring treatment with antiviral agents.
 ► Current treatment with anti-tumour necrosis factor 
(TNF)-α therapy or anti-TNF-α discontinuation 
within previous 16 weeks.
 ► A history of pulmonary tuberculosis infection.
 ► Any absolute contraindication to intravenous 
corticosteroid.
 ► History of malignancy (with the exception of non-mel-
anoma skin cancer) or colonic dysplasia.
 ► Rectal therapy in previous 14 days (substudy exclusion 
only).
 ► Receipt of another IMP as part of a Clinical Trial of an 
Investigational Medicinal Product within the previous 
16 weeks.
outcome measures
Primary outcome
The primary outcome of the trial will be the incidence 
of medical (ie, infliximab or ciclosporin) or surgical 
rescue therapy (colectomy) within 10 days following the 
commencement of intravenous corticosteroid therapy.
For the purposes of the primary endpoint analysis, the 
time point of the start of rescue therapy will be as follows:
 ► Medical rescue therapy: date and approximate time of 
first treatment administration.
 ► Surgical rescue therapy: date and approximate time 
of start of surgery.
Secondary outcomes
1. Incidence of colectomy within 98 days following com-
mencement of intravenous corticosteroid therapy.
2. Burden of disease activity, measured by daily MTWSI 
scores over Days 1–5 after initial IMP administration.
3. Time to clinical response (defined as second consecu-
tive day with MTWSI <10) (Time to clinical response is 
measured during the IMP treatment phase only).
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4. Time to medical or surgical rescue therapy, measured 
according to the time after the first dose of intravenous 
corticosteroids until the time that rescue therapy oc-
curs (using definitions as set out in the primary end-
point). Data will be captured up to the same time point 
as the primary endpoint.
5. Incidence of serious adverse events (SAE), measured 
until Day 10 (+3) following commencement of IMP 
treatment.
Exploratory outcomes
1. Patient-reported quality of life (EuroQol five dimen-
sions, (EQ-5D)30 and Crohn’s and Ulcerative Colitis 
Questionnaire-32 (CUCQ-32)31) at baseline and at 
3 and 6 months following commencement of IMP 
treatment.
The EQ-5D is a widely used generic health-related qual-
ity of life measure featuring self-assessment questions 
distributed across five domains. The CUCQ-32 is an 
inflammatory bowel disease (IBD)-specific question-
naire which captures information related to a patient’s 
well-being during their daily routine. Both question-
naires have been validated.32 33
2. Endoscopic response at Day 3 (±1 day) (via stan-
dardised endoscopic scoring completed by a local and 
a central blinded assessor) following commencement 
of IMP treatment (endoscopic substudy group only).
In addition to the above exploratory endpoints, the trial 
will also perform further exploratory analyses related to 
the identification of biomarkers and treatment response 
predictors, as well as characterisation of the stool micro-
bial response to anakinra. Finally, patient readmission 
and colectomy data (eg, via HES) may be examined to 
investigate the impact of treatment in the longer term.
trial treatment
For the purpose of this trial, the following are considered 
the IMP:
 ► Anakinra solution for injection.
 ► Placebo to match anakinra solution for injection.
IMP is supplied in commercial prefilled syringe config-
urations (100 mg/0.67 mL), packed into trial-specific 
participant kits containing 11 prefilled syringes. The 
syringes and kits have blinded labelling and are identi-
fied by unique pack (kit) numbers. IMP will be stored 
in accordance with the requirements of the Summary of 
Product Characteristics for Anakinra.34
Participants will receive an initial loading dose of 100 mg 
IMP given intravenously within 36 hours of first intra-
venous corticosteroids. This will be followed by 100 mg 
subcutaneous IMP given twice daily, over a maximum of 5 
days (maximum of 10 doses).
Intravenous methylprednisolone or hydrocortisone, 
as per local guidelines for ASUC standard care, will be 
administered to participants as non-IMPs. Participants 
will continue to be treated with routine concomitant 
medications for other comorbidities as appropriate 
within their current clinical condition, with modifications 
(eg, oral to intravenous switches), or temporary cessation 
as necessary. Appropriate supportive care may also be 
prescribed, including fluids, nutritional supplements and 
other medications as necessary.
Participants will return to their normal standard of care 
as defined by their local physicians, following completion 
of trial treatment.
treatment termination and trial withdrawal
Participants may choose to withdraw from treatment or 
the full study at any stage without prejudice to standard 
clinical care.
Clinicians should cease treatment with the study 
drug according to their judgement or under any of the 
following criteria:
 ► Withdrawal of consent for treatment administration.
 ► Development of renal impairment (eGFR <60 mL/
min/1.73 m2) or severe hepatic impairment (Child-
Pugh grade C).
 ► Development of neutropenia (neutrophil 
count <1.5×109/L).
 ► Detection of a significant GI pathogen in stool 
specimen.
 ► Sufficient recovery to allow for cessation of intrave-
nous steroids.
 ► Hospital discharge due to recovery.
 ► Decision to commence medical or surgical rescue 
therapy.
 ► CMV reactivation necessitating treatment with anti-
viral agents (in the judgement of treating clinicians).
 ► The development of an SAE necessitating termina-
tion of IMP treatment.
Where possible, trial assessments will continue following 
treatment termination.
In addition to the treatment termination criteria, 
the following criteria would result in participant with-
drawal from the trial, with no further assessments being 
performed:
 ► Withdrawal of consent for further assessments and 
data collection.
 ► Death.
randomisation and stratification
All patients screened for the trial will be assigned a unique 
participant ID number. Suitable participants will subse-
quently be randomised (1:1) to drug:placebo using an 
online randomisation system accessible via password-pro-
tected access. Randomisation will be stratified for two 
variables:
 ► Previous or current therapy with any of: immu-
nomodulators (azathioprine, 6-mercaptopurine, 
6-thioguanine, methotrexate, ciclosporin), biologics 
(anti-TNF-α monoclonal antibodies, anti-adhesion 
molecule antibodies, other anti-cytokine antibodies) 
or oral Janus kinase inhibitors.
 ► Current or previous oral corticosteroid prescrip-
tion(s) within 8 weeks prior to first dose of intrave-
nous corticosteroids.
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blinding
Trial participants, research teams and site pharmacies will 
be blinded to the treatment group for the duration of the 
trial.
Procedures and assessments
Participant identification and informed consent
We will recruit inpatients with ASUC. Identification of 
potential participants will be undertaken by the clinical 
team with subsequent consenting and trial-specific proce-
dures carried out by the research team.
A total of 40 individuals will be asked to join an optional 
scientific substudy cohort. Participants can decline to 
participate in the substudy but still participate in the 
main study.
Anonymised data on all participants who are 
approached will be collated in accordance with Consoli-
dated Standards of Reporting Trials guidelines.
Screening
The tests required for screening all form part of stan-
dard clinical care, therefore no additional tests will be 
performed other than a urine β-human chorionic gonad-
otropin test for females where there is a possibility of 
pregnancy.
Baseline
The following activities will be performed and recorded 
at baseline:
 ► Medical history review.
 ► Review of blood parameters (haemoglobin, total white 
cell, neutrophil, lymphocyte, monocyte, platelet, 
albumin and C-reactive protein) following a blood 
test performed as part of standard care.
 ► Three research blood samples (one plasma tube, one 
nucleic acid tube, one genotyping tube).
 ► Concomitant medications review.
 ► Demographics.
 ► MTWSI assessment.
 ► Stool sample collection.
 ► EQ-5D and CUCQ-32 questionnaires.
Randomisation and post-baseline procedures
Following baseline data collection, participants will be 
randomised and allocated treatment as described above.
Prior to the first administration of IMP (Day 0), the 
following assessments will be performed:
 ► Review of adverse events (AE).
 ► Recording of any changes to concomitant medication 
since the last assessment.
 ► Confirmation that IMP administration can proceed, 
according to the following criteria:
 – The time of administration of the first IMP dose 
falls no later than 36 hours following the time of 
first dose of intravenous corticosteroid.
 – Intravenous corticosteroid therapy remains ongo-
ing at the time of administration of the first IMP 
dose (ie, that a decision to discontinue corticoste-
roids or transition to oral steroids has not been 
made after the time of participant consent to par-
ticipate in the trial and before the time of the ad-
ministration of the first IMP dose).
 – A firm decision to start rescue therapy or perform 
emergency colectomy has not already been taken.
During the days subsequent to the first dose of trial 
medication, the following activities will be recorded 
daily up to and including Day 5 following IMP treatment 
initiation:
 ► MTWSI assessment/review of standard care clin-
ical MTWSI assessment domains (Not recorded for 
patients who have undergone colectomy).
 ► Recording of any changes to concomitant medication 
prescription since the last assessment.
 ► Review of blood parameters (haemoglobin, total white 
cell, neutrophil, lymphocyte, monocyte, platelet, 
albumin and C-reactive protein) following blood tests 
performed as part of standard care.
 ► Two research blood samples (one plasma tube, one 
nucleic acid tube) (A minimum of one sample every 
72 hours should be taken. Wherever possible, every 
effort should be made to obtain the samples every day 
(up to 10 samples)). 
 ► Review of AEs.
 ► Medical or surgical (emergency colectomy) rescue 
therapy assessment.
 ► Stool sample collection on Day 5 (±1 day) following 
commencement of IMP.
Substudy-only assessments
In addition to the daily assessments described above for 
Days 1–5, the scientific substudy group will undergo an 
additional optional flexible sigmoidoscopy (without bowel 
preparation) on Day 3 (±1 day) following commence-
ment of IMP. This will be performed during their index 
inpatient admission.
Findings will be recorded according to a standardised 
endoscopic scoring system (Mayo)35 by local and central 
blinded assessors. Histology will be scored on up to a 
maximum of six biopsies taken from each of the rectum 
and sigmoid colon, according to validated scoring systems 
for colitis severity at the end of the trial.36–38
Where possible, endoscopic scores, written summary 
reports and photographic recordings (video or static 
images) of sigmoidoscopies will be sent to the central 
trial team for verification of local scoring. In addition, 
where available, data collected as part of standard care 
(non-substudy) endoscopies will be used to supplement 
trial-specific data. These will be scored by the blinded 
central assessor.
Follow-up
Following the participants’ inpatient stay, the following 
assessments will occur:
 ► Day 10 (+3) following commencement of IMP treat-
ment—rescue therapy assessment (In the event that 
a participant is discharged prior to Day 10 without 
having started rescue therapy, a member of the trial 
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team will contact the participant on Day 10 (+3 days) 
to confirm that the participant remains out of hospital 
and has not received rescue therapy elsewhere since 
discharge. If the participant is not contactable, local 
hospital records will be checked for admission).
 ► Day 10 (+3) following commencement of IMP treat-
ment—AE monitoring.
 ► Day 98 (+14) following commencement of IMP 
treatment—colectomy assessment (If not previously 
recorded, a member of the trial team will contact the 
participant on Day 98 (+14) to confirm that the partic-
ipant remains out of hospital and has not undergone 
a colectomy since discharge. If the participant is not 
contactable, local hospital records will be checked for 
admission).
 ► Approximately 3 and 6 months following commence-
ment of IMP treatment—EQ-5D and CUCQ-32 
questionnaires.
Participant status following discharge, including read-
missions and subsequent surgery, may be assessed using 
patient-specific HES data from the NHS Digital, Data 
Access Request Service. Any data collection would start 
at 1 year after commencement of IMP treatment and 
examination of outcomes via HES data would potentially 
continue for up to 5 years, depending on study outcomes.
safety monitoring and reporting
This section summarises the safety monitoring and 
reporting processes for the trial. Full details of the safety 
processes can be found in the comprehensive protocol 
included as part of the online supplementary material 1.
AEs will be recorded from the point of informed 
consent. Standard regulatory definitions for assessing AE 
seriousness will be used.39
As the IMP has a short half-life (<6 hours) no cumula-
tive or late effects are anticipated. Therefore, recording 
of AEs and reporting of SAEs will be actively monitored 
up to Day 10 (+3 days). Following the end of the active 
monitoring period, investigators are still required to 
report any serious adverse reactions or suspected unex-
pected serious adverse reactions (SUSAR) of which they 
become aware.
Pregnancy reporting is only required for trial partici-
pants while they are receiving IMP and for up to 24 hours 
after their last dose.
Patient and public involvement
Patient involvement was actively sought during the plan-
ning and preparation stage for this trial, and will form a 
key part of the trial as it progresses.
A 10-member patient steering group assisted with trial 
design in an early workshop, reviewed previous versions 
of the trial protocol and assisted with responses to the 
initial funding application review. The group provided 
valuable insight into the acceptability of different dosing 
regimens and into ways to support patients during the 
consent process. The patient information leaflet was 
reviewed by the group. To ensure that the views of the 
wider patient community were sought, an online ques-
tionnaire regarding willingness to participate in inpatient 
research studies in colitis was circulated to members of 
Crohn’s and Colitis UK and responses used to inform trial 
design.
A patient representative will serve as a member of the 
TSC.
statistics and data management
Sample size
We plan to include approximately 214 participants (107 per 
group) in the trial with 40 participants also included in the 
optional endoscopic substudy. Recruitment of 214 patients 
to the main trial will give 85% power to detect a 20% abso-
lute risk reduction (ARR) in the primary endpoint from a 
rate in the control group of 49% testing at the 5% signifi-
cance level.
We have based our estimate of the primary endpoint rate 
on data from the recently completed National Institute for 
Health Research (NIHR)-funded CONSTRUCT trial.40 
This trial recruited 270 patients with ASUC across 52 UK 
sites between 2010 and 2013. In CONSTRUCT, 49% of 
patients admitted with ASUC needed escalation to medical 
rescue therapy following treatment with corticosteroids 
(Professor J Williams, personal communication). Since 
there are no existing estimates of effect size for anakinra 
in ASUC, we chose to power IASO to detect a 20% ARR 
following protocol review by members of the British Society 
of Gastroenterology IBD Clinical Research Group, who 
advised that this was the minimum effect size needed that 
would make a substantial difference to the patient popula-
tion, and which would be broadly in line with effect sizes 
seen in other drugs for moderate to severe colitis.41–43
The scientific substudy based on testing cytokines will 
be performed on 40 participants. The choice of sample 
size is based on power studies in transcriptomic studies 
in UC44 with adjustment for multiple testing, as well as 
pragmatic grounds of cost.
Patient population
Populations to be analysed in the trial are as follows:
 ► Full analysis population: all randomised participants 
who receive at least one dose of IMP.
 ► Randomised population: all randomised participants, 
regardless of whether IMP was received.
 ► Safety population: all consenting participants.
Any further populations may additionally be defined 
within the statistical analysis plan.
Analyses
Primary analysis
We will report summary statistics on the primary and 
secondary endpoints according to treatment group. The 
primary analysis will consist of an estimate, 95% CI and 
p value of the absolute risk difference of the incidence rates 
of the need for medical or surgical rescue therapy within 10 
days following the first administration of intravenous corti-
costeroids between the two treatment arms, using logistic 
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regression to adjust for important baseline covariates. The 
primary efficacy analysis will be based on the full analysis 
population.
The baseline characteristics will include:
 ► Prior diagnosis of IBD at the point of hospitalisation 
(‘first presentation’).
 ► Prior hospitalisation for ASUC.
 ► Previous or current therapy with any of: immu-
nomodulators (azathioprine, 6-mercaptopurine, 
6-thioguanine, methotrexate, ciclosporin), biologics 
(anti-TNF-α monoclonal antibodies, anti-adhesion 
molecule antibodies, other anti-cytokine antibodies) 
or oral Janus kinase inhibitors.
 ► Current or previous oral corticosteroid prescrip-
tion(s) within 8 weeks prior to first dose of intrave-
nous corticosteroids.
 ► Demographics.
Secondary endpoints will be compared in a similar 
regression model to estimate the treatment effect on an 
appropriate scale of comparison. This will include an 
assessment of the effects of treatment with anakinra on 
the secondary endpoints.
Secondary analyses
The following secondary analyses will be performed in 
the trial:
 ► Analysis of the randomised population.
 ► Complier average causal effect analysis to assess the 
influence of the amount of treatment received, as 
distinct from treatment assigned.
To test the hypothesis that the clinical effects of anak-
inra in ASUC may differ between groups of patients with 
differing levels of prior inflammatory burden, prespeci-
fied subgroup analyses, in the form of estimating treat-
ment-covariate interactions, will be performed on the 
following baseline characteristics:
 ► Prior diagnosis of IBD at the point of hospitalisation 
(‘first presentation’).
 ► Prior hospitalisation for ASUC.
 ► Naïvety to any of: immunomodulators (azathioprine, 
6-mercaptopurine, 6-thioguanine, methotrexate, 
ciclosporin), biologics (anti-TNF-α monoclonal anti-
bodies, anti-adhesion molecule antibodies, other 
anti-cytokine antibodies) or oral Janus kinase inhibi-
tors at the point of hospitalisation.
 ► Receipt of oral corticosteroids within 8 weeks prior to 
first dose of intravenous corticosteroids.
 ► Cases of suspected or confirmed ASUC without 
evidence of CMV reactivation requiring treatment 
with antiviral agents and without evidence of a signif-
icant GI pathogen.
 ► Duration between first dose of intravenous corticos-
teroids and first dose of IMP.
Interim analyses
As part of planned interim analyses, an independent Data 
Monitoring Committee (iDMC) will examine unblinded 
data and provide a recommendation to a TSC as to 
whether the trial should continue at two prespecified 
points detailed below.
After the first 20 participants have been recruited, 
and all completed a minimum of 10 days follow-up (to 
the time of the primary endpoint), trial feasibility will be 
assessed. The trial will be regarded as feasible only if all of 
the following measures are met:
1. ≥10% of eligible participants are recruited (based on 
use of screening logs to determine the percentage of 
eligible participants who are randomised in each site).
2. Adherence to dosing as per protocol (≥80% of partic-
ipants received appropriately prescribed doses within 
any given 24 hours window).
3. Rescue therapy started on or before the seventh day 
following initial intravenous corticosteroid administra-
tion in ≥80% cases where required during the index 
admission (as determined by review of timing of res-
cue therapy administration relative to corticosteroid 
administration by trial investigators).
4. Maintenance of blinding: there should be no evidence 
of unnecessary unblinding of participants or investiga-
tors.
5. No serious safety concerns identified, especially with 
regard to infections or SUSARs.
After the first 100 participants have completed Day 
10 assessments, futility analysis will be performed to test 
the hypothesis that the reduction in absolute risk differ-
ence in the primary outcome is ≥10% using a one-sided 
2.5% significance test using logistic regression on the 
ARR scale. If the hypothesis is rejected, that is, the lower 
limit of a 95% two-sided CI for treatment—control is 
above −10%, then the iDMC will consider the recommen-
dation for the study to stop early for futility. This is equiva-
lent to spending 0.1% from the 15% total beta value set to 
control the type 2 error under the alternative hypothesis 
(49% and 29% rates).45 If the study continues past the 
interim, then the final analysis will not be adjusted for 
the futility analysis, and standard p values and CIs will be 
reported.
data management
All outcome data will be transferred onto a case report 
form (CRF) which will be anonymised. Data captured on 
CRFs will subsequently be stored in a central database 
prior to analysis. Personal identifiable data kept for the 
purposes of questionnaire postage and HES data capture 
will be destroyed at the end of the trial.
Missing data
Due to short and intensive period of follow-up for the 
primary endpoint, we do not anticipate significant 
missing data. Where we are unable to obtain missing 
data within 12 weeks of the 3 or 6-month time points, we 
will employ the standard approaches to management of 
missing quality of life data previously described in the 
CONSTRUCT trial (eg, participant death at question-
naire completion will be recorded as an EQ-5D score of 0 
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and match minimum observed scores for other quality of 
life domains).40
For participants who withdraw consent to treatment, 
permission to continue to acquire data for outcome 
analysis will be sought. For those who do not consent to 
ongoing monitoring, including those who wish to with-
draw entirely from the study, existing data acquired to 
the point of withdrawal will be included in the final study 
analysis, with missing data handled according to stan-
dard missing data methods, including missing-at-random 
(MAR) methods with sensitivity testing for deviation from 
MAR assumptions.
trial end
For regulatory notification purposes, the end of trial will 
be the earliest of:
 ► The receipt of the final, returned 6-month quality of 
life questionnaires.
 ► Six months (+12 weeks) after the last participant 
entered the study (date of questionnaire censoring).
However, participants may enter a period of long-term 
follow-up via HES data examination and the trial would 
remain open to the Ethics Committee until the last partic-
ipant’s HES data capture has been completed.
Ethics and dissemination
IASO has received ethical (17/EE/0347) and Health 
Research Authority approval. The trial is being carried 
out under a Clinical Trial Authorisation from the Medi-
cines and Healthcare products Regulatory Agency.
This is an NIHR-funded trial and the NIHR publishing 
guidelines will be followed. Authorship of final study 
outputs will be assigned in accordance with guidelines set 
out by the International Committee of Medical Journal 
Editors. Plain language summaries of key trial outputs 
will be prepared in conjunction with the patient steering 
group and published on the trial website. This website is 
listed in the patient information leaflet for the benefit of 
all trial participants.
Implications of pragmatic trial design
In designing the Interleukin 1 blockade in Acute 
Severe Colitis (IASO) trial, we have followed a ‘prag-
matic’ approach to trial design. This aims to test our 
intervention under conditions as close to real-life 
routine practice as possible and so produce results 
that can be generalised and applied in routine prac-
tice settings. Another important aspect to consider 
was that, since the intervention targets an early mole-
cule in the inflammatory cascade, and since there are 
already well-established options for rescue therapy, 
we wanted to test the intervention as close as possible 
to the point of recognition of a patient by a treating 
physician as having acute severe ulcerative colitis 
(ASUC). If the intervention is shown to have a positive 
outcome, then the generalisation of the trial findings 
might include consideration of initiation of anakinra 
dosing at the same time as intravenous corticoste-
roids, that is, as part of initial therapy.
For these reasons, we aimed to keep our inclusion 
criteria as broad as possible and minimise exclusion 
criteria. Thus, in essence, almost any patient with ASUC 
capable of giving informed consent can participate in 
IASO. The key criterion is the recognition of ASUC by a 
physician and the judgement that intravenous corticoste-
roids are needed. The use of the modified Truelove and 
Witts severity index (MTWSI) serves as a ‘sense-check’ 
on this physician judgement to ensure that patients with 
too low a burden of inflammation or symptoms are not 
included. We considered and rejected other inclusion 
criteria that might be typically seen in ‘explanatory’ trials 
in inflammatory bowel disease (IBD), such as the use 
of video endoscopy with local or centralised scoring, or 
faecal calprotectin measurement. Although local assess-
ment of the mucosa is widely used in the assessment of 
patients with ASUC, in many centres intravenous cortico-
steroids may be started before this point. Furthermore, 
the use of centralised scoring would introduce delays into 
participant screening to the extent that randomisation 
and dosing would be impossible to achieve prior to the 
point where rescue therapy should be considered. The 
use of physician judgement as the main arbiter for inclu-
sion does risk the inclusion of patients who subsequently 
turn out to have, for example, Crohn’s colitis or even 
infectious colitis, just as does happen in real life with deci-
sions around corticosteroid initiation. We can, of course, 
obtain endoscopic data as well as clinical and histolog-
ical data where available and these are indeed built into 
our analysis plans. But ultimately, IASO seeks to address 
whether a physician encountering a patient who he or 
she believes to have ASUC, on the basis of the evidence 
available, can and should prescribe anakinra in addition 
to corticosteroids. In this regard, more detailed inclu-
sion criteria would not produce a generalisable result, 
while jeopardising timely patient identification and trial 
recruitment.
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